In earnings calls, diabetes tech companies had less to say about tariffs and focused more on future growth.

and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API ...

“As we progress through 2025, we will advance our product portfolio with the launch of our Dexcom G7 15-Day system and continue to advocate for expanded global access to our glucose biosensors ...

As the trend towards the international dispersion of certain value chain activities produces challenges, discover policies to meet these Tax transparency and international co-operation Enhanced ...

The sensor fabrication is accomplished through photolithography and its performance is validated with a commercial terahertz time-domain spectrometer. Glucose solutions of five different ...

Last year, the two companies formed an agreement for Abbott to exclusively make glucose sensors that work with Medtronic’s insulin pumps and pens, and Medtronic would sell the CGMs. The companies did ...

The company’s glucose sensor, positioned on the upper forearm. Credit: Biolinq / BusinessWire. Biolinq has secured $100m in a Series C funding round to support the regulatory approval process in the ...

A variety of continuous glucose monitors (CGM) can accurately check your blood sugar throughout the day via a small sensor inserted under the skin ... FDA and are available over-the-counter, including ...

A study published by the National Institutes of Health (NIH) analysed how accurate and safe the Dexcom G7 (a new version of a continuous glucose monitor) is when used by adults with Type 1 or Type ...